Growth-Related Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Communication Preferences
Sign Out
Sign In | Create Account
  • Growth-Related Disorders Home
    • Products
      Treatment & Diagnostic Test
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Resources Pediatric Growth-Related Disorders (Basics) Adult Growth Hormone Deficiency
    • Treatment Guidelines
      PES & AACE Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources Advocacy & Support Groups
    • Access & Affordability
      Insurance Support & Prescription Savings
  • Sign In
    Create Account
    • Account Settings
    • Communication Preferences
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Macrilen™ (macimorelin) 60 mg for oral solution logo
Important Safety Information
Prescribing Information
  • About Macrilen™
  • Efficacy & Safety
  • Dosing & Administration
  • Coverage & Savings
  • How to Order
  • Resources
Macrilen™ (macimorelin) 60 mg for oral solution logo

For the diagnosis of adult growth hormone deficiency.

Prescribing Information
Important Safety Information

Product forms and resources

Information about Macrilen™ and forms to help with patient support and the testing process.

Product forms and resources

Information about Macrilen™ and forms to help with patient support and the testing process.

Macrilen™ Test Patient Preparation Form
PDF
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Macrilen™ Test Patient Preparation Form
A form you can fill in and provide to your patients to explain how Macrilen™ works and what to expect from the testing process.
Download
Prescribing Information | Important Safety Information
Macrilen™ Co-pay Program Brochure for Professionals
PDF
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Macrilen™ Co-pay Program Brochure for Professionals
Your eligible patients who have been prescribed Macrilen™ may be able to reduce out-of-pocket costs.
Download
Prescribing Information | Important Safety Information

Learn about a potential treatment option for your patients with AGHD.

Find out more
Find out more

Prescribing Information | Important Safety Information

Intended for use by healthcare professionals only

Questions about Macrilen™?

Have you created your novoMEDLINK™ account?

Sign up now to receive news about growth-related disorders and product updates from Novo Nordisk.

Create your account

Selected Important Safety Information for Macrilen™

Warnings and Precautions

  • QT Prolongation: Macrilen™ causes an increase of about 11 msec in the corrected QT (QTc) interval. QT prolongation can lead to development of torsade de pointes-type ventricular tachycardia with the risk increasing as the degree of prolongation increases. The concomitant use of Macrilen™ with drugs that are known to prolong the QT interval should be avoided

Indication and Limitation of Use

Macrilen™ (macimorelin) 60 mg for oral solution is indicated for the diagnosis of adult growth hormone deficiency (AGHD).

  • The safety and diagnostic performance of Macrilen™ have not been established for subjects with a body mass index (BMI) >40 kg/m2

Important Safety Information

Warnings and Precautions

  • QT Prolongation: Macrilen™ causes an increase of about 11 msec in the corrected QT (QTc) interval. QT prolongation can lead to development of torsade de pointes-type ventricular tachycardia with the risk increasing as the degree of prolongation increases. The concomitant use of Macrilen™ with drugs that are known to prolong the QT interval should be avoided
  • Potential for False Positive Test Results with Use of Strong CYP3A4 Inducers: Concomitant use of strong CYP3A4 inducers with Macrilen™ can decrease macimorelin plasma levels significantly and thereby lead to a false positive result. Strong CYP3A4 inducers should be discontinued and enough time should be given to allow washout of CYP3A4 inducers prior to test administration
  • Potential for False Negative Test Results in Recent Onset Hypothalamic Disease: Adult growth hormone (GH) deficiency caused by a hypothalamic lesion may not be detected early in the disease process. Macimorelin acts downstream from the hypothalamus and macimorelin stimulated release of stored GH reserves from the anterior pituitary could produce a false negative result early when the lesion involves the hypothalamus. Repeat testing may be warranted in this situation 

Adverse Reactions

  • The most common adverse reactions are dysgeusia, dizziness, headache, fatigue, nausea, hunger, diarrhea, upper respiratory tract infection, feeling hot, hyperhidrosis, nasopharyngitis, and sinus bradycardia

Please click here for Macrilen™ Prescribing Information.

 

Growth-Related Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Growth-Related Disorders Home
  • Product Information
    Products
    • Treatment & Diagnostic Test
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Resources
      Pediatric Growth-Related Disorders (Basics)
      Adult Growth Hormone Deficiency
    Treatment Guidelines
    • PES & AACE Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
      Advocacy & Support Groups
    Access & Affordability
    • Insurance Support & Prescription Savings

Macrilen™ is a trademark of Aeterna Zentaris GmbH, licensed exclusively in the U.S. and Canada to Novo Nordisk Biopharm Limited.
NovoCare® is a registered trademark and novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2022 Novo Nordisk All rights reserved.  US22MAC00005 September 2022

Quick links

Treatment & diagnostic test

Insurance support & patient savings

Pediatric disorders overview

Clinical education for your patients